Protein Structure Platform

What a Protein Structure Platform is

A protein structure platform serves structural biologists and drug designers working with three-dimensional protein data. It stores predicted and experimental structures, runs structure analysis and comparison, and links structures to sequences, ligands, and experimental evidence.

Its distinguishing challenge is confidence. Predicted structures carry per-residue confidence that varies across the protein, and a drug-design decision based on a low-confidence region is unreliable. The platform must therefore surface confidence alongside every structure, not just the shape itself.

Core features

Structure features keep shapes, confidence, and evidence together.

• Structure repository: Store predicted and experimental structures with source, method, version, and confidence data, searchable by protein, sequence, and ligand.
• Structure visualisation: Visualise structures in three dimensions with confidence colouring, ligand binding sites, and domain annotations, in the browser without specialist software.
• Structure comparison: Compare structures across variants, homologues, and predictions, highlighting regions that differ and regions where confidence is low.
• Ligand and binding-site analysis: Analyse binding pockets, ligand interactions, and druggability indicators for drug-design projects.
• Sequence-structure linkage: Link every structure to its sequence, mutations, and experimental evidence, so a structure is always interpretable in sequence context.
• Project workspaces: Organise structures, analyses, and decisions by project, with shared workspaces for distributed structural biology teams.

How it is built

Build the structure repository and confidence handling first, since analysis without confidence context misleads designers.

1. Structure data model: Define how structures, confidence, sequences, and ligands are stored and linked, validated with structural biologists.
2. Repository and visualisation: Build structure storage and browser-based three-dimensional visualisation with confidence colouring.
3. Comparison tools: Add structure comparison and binding-site analysis for the projects' real questions.
4. Sequence linkage: Add sequence, mutation, and evidence linkage.
5. Collaboration: Add project workspaces and sharing for distributed teams.

Technology considerations

Structure platforms need three-dimensional visualisation in the browser, efficient storage of large structure files, and compute for structure analysis. They must also handle prediction-model versions carefully, since predictions change when models update.

• Browser-based three-dimensional structure visualisation
• Structure storage with confidence and version metadata
• Comparison and binding-site analysis tools
• Sequence-structure linkage with mutation mapping
• Prediction-model version management

Challenges to plan for

Structure platforms fail when confidence is hidden or when structures cannot be compared fairly.

• Confidence blindness: A structure shown without confidence invites over-interpretation. Colour and report confidence everywhere a structure appears.
• Model version drift: Prediction models update and change outputs. Version models explicitly and record which version produced each structure.
• File scale: Structure collections grow large. Use efficient storage and streaming visualisation rather than loading whole collections at once.
• Experimental versus predicted mixing: Experimental and predicted structures have different reliability. Label source clearly and never present them as equivalent.

What to scope before you build

Before scoping, define the protein families, prediction methods, and project types in the first release, and confirm whether ligand docking or molecular dynamics are in scope, since both add major compute and analysis complexity beyond structure management.

How it works in practice

A drug designer opens a predicted structure for a target protein and sees confidence colouring showing a well-predicted binding pocket but a low-confidence flexible loop, so design work focuses on the pocket and treats the loop with caution. The designer compares the structure against a homologue and an experimental structure, notes where they agree and disagree, and selects a ligand series for the pocket with druggability indicators supporting the choice. The project workspace records which structure version and model version informed the decision, so a later model update can be assessed deliberately. Success is measured by design decisions traceable to structure versions, and by how rarely low-confidence regions drive expensive experimental work. The team also tracks how often predicted pockets are confirmed experimentally, building an honest record of where prediction earns trust and where it still needs laboratory proof.

Frequently asked questions